You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
|
|---|---|
| Published in |
Frontiers in oncology, January 2019
|
| DOI | 10.3389/fonc.2019.00006 |
| Pubmed ID | |
| Authors |
Sadamoto Zenda, Yosuke Ota, Naomi Kiyota, Susumu Okano, Masato Fujii, Morimasa Kitamura, Shunji Takahashi, Tsutomu Ueda, Nobuya Monden, Takeharu Yamanaka, Makoto Tahara |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 22% |
| Student > Master | 4 | 17% |
| Other | 2 | 9% |
| Professor > Associate Professor | 2 | 9% |
| Lecturer | 2 | 9% |
| Other | 1 | 4% |
| Unknown | 7 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 43% |
| Environmental Science | 1 | 4% |
| Mathematics | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 8 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 January 2019.
All research outputs
#22,767,715
of 25,385,509 outputs
Outputs from Frontiers in oncology
#15,926
of 22,432 outputs
Outputs of similar age
#385,609
of 446,338 outputs
Outputs of similar age from Frontiers in oncology
#145
of 220 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,432 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,338 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 220 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.